The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study
Open accessAbstract
BACKGROUND: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving antiretroviral therapy (ART) have not been characterized in large populations. OBJECTIVE: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. DESIGN: Cohort study. SETTING: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. PARTICIPANTS: 77 590 HIV-positive persons receiving ART. MEASUREMENTS: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction-confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafenamide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. RESULTS: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diagnosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. LIMITATION: Residual confounding by comorbid conditions cannot be completely excluded. CONCLUSION: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV. PRIMARY FUNDING SOURCE: Instituto de Salud Carlos III and National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
HIV Infection, Inflammation, Immunosenescence, and Aging
Deeks, S. G. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-042909-093756 · Cited by 1,349
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117592 · Cited by 923
Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
Elfiky, A. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117477 · Cited by 715
HIV-1 infection accelerates age according to the epigenetic clock
Horvath, S., & Levine, A. J. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv277 · Cited by 556
COVID-19 in patients with HIV: clinical case series
Blanco, J. L., Ambrosioni, J., Garcia, F., Martínez, E., Soriano, A., Mallolas, J., & Miro, J. M. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30111-9 · Cited by 414
Self-citationPatterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355
Gross, A. M., Jaeger, P. A., Kreisberg, J. F., Licon, K., Jepsen, K. L., Khosroheidari, M., Morsey, B. M., Swindells, S., Shen, H., Ng, C. T., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.019 · Cited by 306
A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe
Borobia, A., Carcas, A., Arnalich, F., Álvarez-Sala, R., Monserrat-Villatoro, J., Quintana, M., Figueira, J., Torres Santos-Olmo, R., García-Rodríguez, J., Martín-Vega, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061733 · Cited by 288
Self-citationEarly Immune Senescence in HIV Disease
Desai, S., & Landay, A. (2010) · Current HIV/AIDS Reports · doi:10.1007/s11904-009-0038-4 · Cited by 248
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
Härter, G., Spinner, C. D., Roider, J., Bickel, M., Krznaric, I., Grunwald, S., Schabaz, F., Gillor, D., Postel, N., Mueller, M. C., et al. (2020) · Infection · doi:10.1007/s15010-020-01438-z · Cited by 243
Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks
Lipsitch, M., Donnelly, C. A., Fraser, C., Blake, I. M., Cori, A., Dorigatti, I., Ferguson, N. M., Garske, T., Mills, H. L., Riley, S., et al. (2015) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0003846 · Cited by 238
Self-citationAntiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
Park, S.-J., Yu, K.-M., Kim, Y.-I., Kim, S.-M., Kim, E.-H., Kim, S.-G., Kim, E. J., Casel, M. A. B., Rollon, R., Jang, S.-G., et al. (2020) · mBio · doi:10.1128/mbio.01114-20 · Cited by 185
Wang, W., Su, B., Pang, L., Qiao, L., Feng, Y., Ouyang, Y., Guo, X., Shi, H., Wei, F., Su, X., et al. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0447-2 · Cited by 134
Melchjorsen, J., Risør, M. W., Søgaard, O. S., O’Loughlin, K. L., Chow, S., Paludan, S. R., Ellermann‐Eriksen, S., Hedley, D. W., Minderman, H., Østergaard, L. J., et al. (2011) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182185276 · Cited by 73
Cottrell, M. L., Garrett, K. L., Prince, H. M. A., Sykes, C., Schauer, A. P., Emerson, C. W., Peery, A. F., Rooney, J. F., McCallister, S. H., Gay, C. L., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx064 · Cited by 61
Zídek, Z., Franková, D., & Holý, A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3381-3386.2001 · Cited by 52
Frailty, markers of immune activation and oxidative stress in HIV infected elderly
Álvarez, S., Brañas, F., Sánchez‐Conde, M., Moreno, S., de Quirós, J. C. L. B., & Muñoz‐Fernández, M. Á. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230339 · Cited by 47
Self-citationZídek, Z., Potměšil, P., Kmoníèková, E., & Holý, A. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02110-1 · Cited by 40
Chen, X. P., & Cao, Y. (2004) · Clinical Infectious Diseases · doi:10.1086/386340 · Cited by 34
Frailty Phenotype: A Clinical Marker of Age Acceleration in the Older HIV-Infected Population
Sánchez‐Conde, M., Rodríguez-Centeno, J., Dronda, F., López, J. C., Jiménez, Z., Berenguer, J., Pérez-Elías, M. J., Moreno, S., Rodés, B., & Brañas, F. (2019) · Epigenomics · doi:10.2217/epi-2018-0130 · Cited by 24
Self-citationKostecká, P., Holý, A., Farghali, H., Zı́dek, Z., & Kmonı́čková, E. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.12.005 · Cited by 11
Cited by
Long covid—mechanisms, risk factors, and management
Crook, H., Raza, S., Nowell, J., Young, M., & Edison, P. (2021) · BMJ · doi:10.1136/bmj.n1648 · Cited by 1,655
Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, S. A., Boulle, A., Davies, M.-A., Hussey, H., Ismail, M., Morden, E., Vundle, Z., Zweigenthal, V., Mahomed, H., Paleker, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1198 · Cited by 565
Bhaskaran, K., Rentsch, C. T., MacKenna, B., Schultze, A., Mehrkar, A., Bates, C. J., Eggo, R. M., Morton, C. E., Bacon, S. C. J., Inglesby, P., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30305-2 · Cited by 470
COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State
Tesoriero, J. M., Swain, C.-A. E., Pierce, J. L., Zamboni, L., Wu, M., Holtgrave, D. R., Gonzalez, C. J., Udo, T., Morne, J. E., Hart-Malloy, R., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.37069 · Cited by 391
Ssentongo, P., Heilbrunn, E. S., Ssentongo, A. E., Advani, S., Chinchilli, V. M., Nunez, J. J., & Du, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-85359-3 · Cited by 325
Metadata
- Authors
- del Amo, J., Polo, R., Moreno, S., Díaz, A., Martínez, E., Arribas, J. R., Jarrín, I., & Hernán, M. A.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2020-10-06
- Volume
- 173
- Issue
- 7
- Pages
- 536-541
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W3157063593
- Cited by
- 324
- References
- 26
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.